Hauschild, Paul Robert
http://hdl.handle.net/10400.14/43430.  , 2023

Rogiers, Aljosja ; Pires da Silva, Ines ; Tentori, Chiara...
https://mediatum.ub.tum.de/1653383.  , 2021

Rogiers, Aljosja ; Da Silva, Ines Pires ; Tentori, Chiara...
Rogiers , A , Da Silva , I P , Tentori , C , Tondini , C A , Grimes , J M , Trager , M H , Nahm , S , Zubiri , L , Manos , M , Bowling , P , Elkrief , A , Papneja , N , Vitale , M G , Rose , A A N , Borgers , J S W , Roy , S , Mangana , J , Pimentel Muniz , T , Cooksley , T , Lupu , J , Vaisman , A , Saibil , S D , Butler , M O , Menzies , A M , Carlino , M S , Erdmann , M , Berking , C , Zimmer , L , Schadendorf , D , Pala , L , Queirolo , P , Posch , C , Hauschild , A , Dummer , R , Haanen , J , Blank , C U , Robert , C , Sullivan , R J , Ascierto , P A , Miller , W H , Stephen Hodi , F , Suijkerbuijk , K P M , Reynolds , K L , Rahma , O E , Lorigan , P C , Carvajal , R D , Lo , S , Mandala , M & Long , G V 2021 , ' Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition ' , Journal for ImmunoTherapy of Cancer , vol. 9 , no. 1 , e001931 . https://doi.org/10.1136/jitc-2020-001931.  , 2021

Rogiers, Aljosja ; Pires da Silva, Ines ; Tentori, Chiara...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817383/.  , 2021

Eggermont, Alexander MM ; Meshcheryakov, Andrey ; Atkinson, Victoria...
Eggermont , A MM , Meshcheryakov , A , Atkinson , V , Blank , C U , Mandala , M , Long , G V , Barrow , C , Di Giacomo , A M , Fisher , R , Sandhu , S , Kudchadkar , R , Ortiz Romero , P L , Svane , I M , Larkin , J , Puig , S , Hersey , P , Quaglino , P , Queirolo , P , Stroyakovskiy , D , Bastholt , L , Mohr , P , Hernberg , M , Chiarion-Sileni , V , Strother , M , Hauschild , A , Yamazaki , N , van Akkooi , A CJ , Lorigan , P , Krepler , C , Ibrahim , N , Marreaud , S , Kicinski , M , Suciu , S & Robert , C 2021 , ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ' , European Journal of Cancer , vol. 158 , pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023.  , 2021

Eggermont, Alexander Mm ; Meshcheryakov, Andrey ; Atkinson, Victoria...
Eggermont , A M , Meshcheryakov , A , Atkinson , V , Blank , C U , Mandala , M , Long , G V , Barrow , C , Di Giacomo , A M , Fisher , R , Sandhu , S , Kudchadkar , R , Ortiz Romero , P L , Svane , I M , Larkin , J , Puig , S , Hersey , P , Quaglino , P , Queirolo , P , Stroyakovskiy , D , Bastholt , L , Mohr , P , Hernberg , M , Chiarion-Sileni , V , Strother , M , Hauschild , A , Yamazaki , N , van Akkooi , A C , Lorigan , P , Krepler , C , Ibrahim , N , Marreaud , S , Kicinski , M , Suciu , S & Robert , C 2021 , ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ' , European journal of cancer (Oxford, England : 1990) , vol. 158 , pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023.  , 2021